Dr Reddy's Laboratories (FRA:RDDA) Quality Rank

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:RDDA Dr Reddy's Laboratories Ltd FRA:RDDA
92 GF Score
Price €10.80
GF Value €12.64
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Dr Reddy's Laboratories Quality Rank?

The Quality Rank measures the business quality of a company relative to other companies. It is ranked based on the strength of the balance sheet, as well as the profitability and growth of the business. The ranked companies are split in equal numbers and then ranked from 1 to 10, with 10 being the highest.

The rank of balance sheet (30%)

The rank of balance sheet is done through the ranking of:
  • Interest coverage
  • Zscore
  • Debt to revenue
  • Equity to asset
  • Cash to debt

The rank of Profitability (70%)

The ranking of Profitability is done by ranking:
  • Operating margin mean rank (10-year mean average profit margine)
  • Operating margin growth rank
  • Fscore
  • Predictability rank
  • Revenue growth rank (5 year), when the growth is higher than 25%, set it as 25%
  • Num of year profit (number of years that is profitable within the last 10 years)
  • ROIC median (10-year median of ROIC)

Dr Reddy's Laboratories Quality Rank Related Terms

FRA:RDDA
92GF Score
Dr Reddy's Laboratories Ltd FRA:RDDA
Quality Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Dr Reddy's Laboratories (FRA:RDDA) Overvalued in 2026?

Based on GuruFocus' analysis, Dr Reddy's Laboratories stock appears to be undervalued. The current stock price of €10.80 is trading 14.6% below its estimated GF Value™ of €12.64. GuruFocus considers Dr Reddy's Laboratories to be Modestly Undervalued.

Key valuation signals for FRA:RDDA:

  • Quality Rank:
  • GF Value™: €12.64 vs. price of €10.80 (14.6% below fair value)
  • GF Score™: 92/100 with 3 warning signs

No single metric tells the full story. See the FRA:RDDA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Dr Reddy's Laboratories Business Description

Address 8-2-337, Road No. 3, Banjara Hills, Hyderabad, TG, IND, 500 034
Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly 40% of its generics sales, with other key markets being India (20%) and Europe (20%). Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.
92GF Score

Get the complete analysis for FRA:RDDA

Quality Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€10.80
Price
€12.64
GF Value